A New Histone Deacetylase Inhibitor, MHY219, Inhibits the Migration of Human Prostate Cancer Cells via HDAC1
Biomolecules & Therapeutics
;
: 434-441, 2015.
Artículo
en Inglés
| WPRIM
| ID: wpr-36716
ABSTRACT
Histone deacetylase (HDAC) inhibitors are considered novel agents for cancer chemotherapy. We previously investigated MHY219, a new HDAC inhibitor, and its potent anticancer activity in human prostate cancer cells. In the present study, we evaluated MHY219 molecular mechanisms involved in the regulation of prostate cancer cell migration. Similar to suberanilohydroxamic acid (SAHA), MHY219 inhibited HDAC1 enzyme activity in a dose-dependent manner. MHY219 cytotoxicity was higher in LNCaP (IC50=0.67 muM) than in DU145 cells (IC50=1.10 muM) and PC3 cells (IC50=5.60 muM) after 48 h of treatment. MHY219 significantly inhibited the HDAC1 protein levels in LNCaP and DU145 cells at high concentrations. However, inhibitory effects of MHY219 on HDAC proteins levels varied based on the cell type. MHY219 significantly inhibited LNCaP and DU145 cells migration by down-regulation of matrix metalloprotease-1 (MMP-1) and MMP-2 and induction of tissue inhibitor of metalloproteinases-1 (TIMP-1). These results suggest that MHY219 may potentially be used as an anticancer agent to block cancer cell migration through the repression of MMP-1 and MMP-2, which is related to the reduction of HDAC1.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Próstata
/
Neoplasias de la Próstata
/
Represión Psicológica
/
Histonas
/
Regulación hacia Abajo
/
Movimiento Celular
/
Metaloproteinasas de la Matriz
/
Quimioterapia
/
Inhibidores de Histona Desacetilasas
/
Histona Desacetilasas
Límite:
Humanos
Idioma:
Inglés
Revista:
Biomolecules & Therapeutics
Año:
2015
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS